Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etersalate SCHEMBL24764 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1LMNATDP1 | |
| SCHEMBL14544527 | 0.77 | ALDH1A1 (0.71) | ALDH1A1KMT2AMEN1LMNATDP1 | |
| SCHEMBL11111056 | 0.77 | ALDH1A1 (0.80) | ALDH1A1KMT2AMEN1LMNATDP1 | |
| SCHEMBL11345112 | 0.76 | CNR1 (0.55) | ALDH1A1KMT2AMEN1LMNACYP1A2 | |
| SCHEMBL10802880 | 0.75 | ALDH1A1 (0.77) | ALDH1A1KMT2AMEN1LMNATDP1 | |
| SCHEMBL11663255 | 0.75 | MEN1 (0.63) | ALDH1A1KMT2AMEN1LMNATDP1 | |
| SCHEMBL11589528 | 0.75 | PTGS2 (0.55) | ALDH1A1LMNATDP1CYP1A2 | |
| Diacetamate SCHEMBL863106 | 0.75 | KMT2A (0.81) | ALDH1A1KMT2AMEN1LMNATDP1 | |
| Aspirin SCHEMBL10380307 | 0.75 | KMT2A (0.63) | ALDH1A1KMT2AMEN1LMNATDP1 | |
| SCHEMBL27993616 | 0.74 | PTGS2 (0.51) | ALDH1A1LMNATDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| WO-2013093320-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | ARG1, TYR, NOS1 | ALDH1A1 108/4885KMT2A 1478/4885MEN1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.